← Eichor
Study identifier: NCT06547398 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Prostate Adaptive Radiation Therapy

Condition: Prostatic Neoplasms  ·  Sponsor: Royal North Shore Hospital

PhaseNA
Planned participants130
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Prostate ART is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for prostate cancer patients. Adaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced. Phase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. If phase 1 of this study is safe and feasible, the study will proceed to phase 2. Part 2 of the study looks at using adaptive technology to reduce radiation treatment margins. The primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side effects for prostate cancer patients.

This description comes directly from the study's public registry record.

Talk to the study team

Nada Cheikh-Ali  ·  +61294631345  ·  nada.cheikhali@health.nsw.gov.au

Heidi Tsang  ·  +61294631340  ·  heidi.tsang@health.nsw.gov.au

Always discuss trial participation with your own doctor first.

Locations (1)

Northern Sydney Cancer Centre, Royal North Shore HospitalSt Leonards, New South Wales, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06547398